News Releases

Date Title and Summary Additional Formats
Toggle Summary HTG Molecular Diagnostics to Announce Fourth Quarter and Year-End Financial Results and Host Conference Call on Thursday, March 22
TUCSON, Ariz. , March 07, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced that it will report its financial results for the quarter and year ended December 31, 2017 after
View HTML
Toggle Summary HTG Announces New Australian Patent for Its Technology
Patent covers methods of co-detecting mRNA and small non-coding RNA TUCSON, Ariz. , Feb. 26, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced the issuance of Australian
View HTML
Toggle Summary HTG Molecular Diagnostics to Present at the LEERINK Partners 7th Annual Global Healthcare Conference
TUCSON, Ariz. , Feb. 07, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a provider of instruments, reagents and services for molecular profiling applications, today announced that management will present in a fireside chat at the LEERINK Partners 7th Annual Global
View HTML
Toggle Summary HTG Molecular Diagnostics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
TUCSON, Ariz. , Jan. 23, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a provider of instruments, reagents and services for molecular profiling applications, today announced the completion of its previously announced underwritten public offering of 13,915,000 shares
View HTML
Toggle Summary HTG Molecular Diagnostics Announces Pricing of Public Offering of Common Stock
TUCSON, Ariz. , Jan. 18, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a provider of instruments, reagents and services for molecular profiling applications, today announced the pricing of an underwritten public offering of 12,100,000 shares of its common stock at a
View HTML
Toggle Summary HTG Molecular Diagnostics Announces Proposed Public Offering of Common Stock
TUCSON, Ariz. , Jan. 16, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a provider of instruments, reagents and services for molecular profiling applications, today announced that it intends to offer and sell, subject to market and other conditions, 10,000,000 shares
View HTML
Toggle Summary HTG Molecular Announces Third Statement of Work for New Clinical Assay Development Program
TUCSON, Ariz. , Jan. 16, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (NASDAQ:HTGM) (HTG), a provider of instruments, reagents and services for molecular profiling applications, today announced it has entered into a third statement of work for a new clinical assay development program
View HTML
Toggle Summary HTG Announces Preliminary Fourth Quarter and Full Year 2017 Unaudited Financial Results and Provides Initial 2018 Revenue Guidance
Fourth quarter 2017 revenue expected to be between $6.9 and $7.2 million Full year 2017 revenue expected to be between $13.8 and $14.1 million Initial full year 2018 revenue guidance of $20.0 to $25.0 million TUCSON, Ariz. , Jan. 04, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc.
View HTML
Toggle Summary HTG Molecular Diagnostics Expands its Collaboration with Merck KGaA, Darmstadt, Germany
Signs Master Collaboration Agreement for Assay Development and Manufacturing of Kits Supporting Biomarker Research Programs TUCSON, Ariz. and DARMSTADT, Germany , Dec. 26, 2017 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for
View HTML
Toggle Summary HTG Molecular Diagnostics to Participate in Corporate Access Event in San Francisco, January 8 – 10, 2018
TUCSON, Ariz. , Dec. 20, 2017 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (NASDAQ:HTGM), a provider of instruments, reagents and services for molecular profiling applications, today announced that its senior management team will host institutional investor and partnering meetings at the
View HTML